## **IN THE CLAIMS**

Claim 1 (Currently Amended) An imino-azolinone-vinyl fused-benzene compound or its salt according to Formula (I),

$$\begin{array}{c|c}
R^2 & R^1 \\
\hline
A & X \\
\hline
NH & (I)
\end{array}$$

wherein A is an 5-8 membered heterocyclic group or an carbocyclic group which may be fused with an aryl, an heteroaryl, an cycloalkyl or an heterocycloalkyl;

X is S, O or  $-NR^3$ ;

Y is S or O;

R<sup>1</sup> is selected from the group consisting of H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfanyl, sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino and carbamate;

 $R^2 \ is \ selected \ from \ the \ group \ consisting \ of \ H, \ halogen, \ acyl, \ amino, \ C_1-C_6-alkyl, \ C_2-C_6-alkynyl, \ C_1-C_6-alkyl \ carboxy, \ C_1-C_6-alkyl \ acyl, \ C_1-C_6-alkyl \ acyloxy, \ C_1-C_6-alkyl \ alkoxy, \ C_1-C_6-alkyl \ alkyl \ acyloxyl, \ C_1-C_6-alkyl \ acyloxyl,$ 

cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl;

G is a  $C_1$ - $C_6$ -alkoxy, <u>unsubstituted</u>  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, <u>unsubstituted</u>  $C_1$ - $C_6$ -alkyl aryl, or a sulfonyl moiety;

 $R^3$  is selected from the group consisting of H and  $C_1$ - $C_6$ -alkyl; with the proviso that the following 8 compounds are excluded:

Claim 2 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 1, wherein A is selected from the group consisting of 2H-(benzo-1, 3-dioxolanyl), 2H, 3H-benzo-1,4-dioxanyl, 2,3-dihydrobenzofuranyl, anthraquinonyl, 2,2-difluorobenzo-1,3-dioxolenyl, 1,3-dihydrobenzofuranyl, benzofuranyl, 4-methyl-2H-benzo-1,4-oxazin-3-onyl, pyridinyl, pyrazinyl, and 4-methyl-2H, 3H-benzo-1,4-oxazinyl.

÷

Claim 3 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 2, wherein A is a dioxolenyl or a pyridinyl moiety.

Claim 4 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 1, wherein R<sup>1</sup>, R<sup>2</sup>, or R<sup>1</sup> and R<sup>2</sup> are H.

Claim 5 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 1, wherein G is a  $C_1$ - $C_6$ -alkoxy, or a sulfonyl moiety.

Claim 6 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 1, wherein G is a  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkynyl, or a  $C_1$ - $C_6$ -alkyl aryl moiety.

Claim 7 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 1, wherein G is a sulfonyl moiety of the formula –SO<sub>2</sub>-R<sup>4</sup>, wherein R<sup>4</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, heteroaryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl-heteroaryl, carboxy, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, acylamino, and sulfonylamino.

Claim 8 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 7, wherein  $R^4$  is aryl, heteroaryl or  $C_1$ - $C_3$  alkyl.

Claim 9 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 1, wherein X is S, Y is O,  $R^1$  and  $R^2$  are H, and A is a dioxolenyl or pyridinyl moiety.

Claim 10 (Previously Presented): The imino-azolinone-vinyl fused-benzene compound or its salt according to claim 1, selected from the group consisting of:

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-2-chloro-benzene sulfonamide;

Ethanesulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-3-chloro-benzene sulfonamide;

5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonic acid (5-benzo[1,3]dioxol-5-yl methylene -4-oxo-thiazolidin-2-ylidene)-amide;

3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester;

6-Chloro-pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

Quinoline-8-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-methane sulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-4-methyl-benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-methanesulfonamide;

Biphenyl-2-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

Pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

3-(4-Oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester;

2-Chloro-N-(4-oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidene)-benzene sulfonamide;

3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid;

5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione-2-(O-methyl-oxime);

5-Benzo[1,3]dioxol-5-ylmethylene-2-benzylimino-thiazolidin-4-one;

2-Benzylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;

2-Propylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;

5-Benzo[1,3]dioxol-5-ylmethylene-2-propylimino-thiazolidin-4-one; and

5-(4-Dimethylamino-quinazolin-6-ylmethylene)-2-methylamino-thiazol-4-one.

Claim 11 (Currently Amended): A composition comprising a carrier, adjuvant, diluent, excipient, or a combination thereof and an imino-azolinone-vinyl fused-benzene compound or its salt according to Formula (I)

$$\begin{array}{c|c}
R^2 & R^1 \\
\hline
A & X \\
\hline
N - G \\
\hline
N + MH
\end{array}$$
(I)

wherein A is an 5-8 membered heterocyclic group or an carbocyclic group which may be fused with an aryl, an heteroaryl, an cycloalkyl or an heterocycloalkyl;

X is S, O or  $-NR^3$ ;

Y is S or O;

R<sup>1</sup> is selected from the group consisting of H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino and carbamate;

 $R^2$  is selected from the group consisting of H, halogen, acyl, amino,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkyl carboxy,  $C_1$ - $C_6$ -alkyl acyl,  $C_1$ - $C_6$ -alkyl alkoxycarbonyl,  $C_1$ - $C_6$ -alkyl aminocarbonyl,  $C_1$ - $C_6$ -alkyl acyloxy,  $C_1$ - $C_6$ -alkyl acylamino,  $C_1$ - $C_6$ -alkyl ureido,  $C_1$ - $C_6$ -alkyl carbamate,  $C_1$ - $C_6$ -alkyl amino,  $C_1$ - $C_6$ -alkyl alkoxy,  $C_1$ - $C_6$ -alkyl sulfanyl,  $C_1$ - $C_6$ -alkyl sulfonyl,  $C_1$ - $C_6$ -alkyl sulfonylaminoaryl, aryl, heteroaryl,  $C_3$ - $C_8$ -cycloalkyl,  $C_3$ - $C_8$ -heterocycloalkyl,  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl,  $C_2$ - $C_6$ -alkenyl-aryl,  $C_2$ - $C_6$ -alkenyl-heteroaryl,  $C_2$ - $C_6$ -alkynyl aryl,  $C_2$ - $C_6$ -alkynyl -heteroaryl, carboxy, cyano, hydroxy,  $C_1$ - $C_6$ -alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl;

G is a  $C_1$ - $C_6$ -alkoxy, <u>unsubstituted</u>  $C_1$ - $C_6$ -alky,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, <u>unsubstituted</u>  $C_1$ - $C_6$ -alkyl aryl, or a sulfonyl moiety;

 $R^3$  is selected from the group consisting of H and  $C_1$ - $C_6$ -alkyl; with the proviso that the following 4 compounds are excluded:

Claim 12 (Withdrawn-Currently Amended): A method of treating or preventing at least one disease in a patient in need thereof, comprising administering an imino-azolinone-vinyl fused-benzene or its salt according to Formula (I)

wherein A is an 5-8 membered heterocyclic group or an carbocyclic group which may be fused with an aryl, an heteroaryl, an cycloalkyl or an heterocycloalkyl;

X is S, O or  $-NR^3$ ;

Y is S or O;

R<sup>1</sup> is selected from the group consisting of H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl,

C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino and carbamate;

R<sup>2</sup> is selected from the group consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, heteroaryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl-heteroaryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl;

G is a <u>unsubstituted</u>  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkyenyl,  $C_2$ - $C_6$ -alkynyl, heteroaryl, <u>unsubstituted</u>  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl,  $C_2$ - $C_6$ -alkenyl-aryl or -heteroaryl,  $C_2$ - $C_6$ -alkynyl aryl or -heteroaryl,  $C_1$ - $C_6$ -alkoxy,  $C_1$ - $C_6$ -acyl, or a sulfonyl moiety;

 $R^3$  is selected from the group comprising or consisting of H or  $C_1$ - $C_6$ -alkyl; to the patient in need thereof in an amount sufficient to treat or prevent the at least one disease; wherein the at least one disease is selected from the group consisting of

autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, platelet aggregation, cancer, transplantation, graft rejection, lung injuries, and a combination thereof.

Claim 13 (Withdrawn): The method of claim 12, wherein G is a C<sub>1</sub>-C<sub>6</sub>-alkoxy, or a sulfonyl moiety.

<u>.</u>

Claim 14 (Withdrawn): The method of claim 12, wherein the imino-azolinone-vinyl fused-benzene compound or its salt is selected from the group consisting of:

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-2-chloro-benzene sulfonamide;

Ethanesulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-3-chloro-benzene sulfonamide;

5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonic acid (5-benzo[1,3]dioxol-5-yl methylene -4-oxo-thiazolidin-2-ylidene)-amide;

3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester;

6-Chloro-pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

Quinoline-8-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin -2-ylidene )-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-benzene sulfonamide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-4-methylbenzene sulfonamide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-methane sulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-4-methyl-benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-methanesulfonamide;

Biphenyl-2-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

Pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

- 3-(4-Oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester;
- 2-Chloro-N-(4-oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidene)-benzene sulfonamide;
- 3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid;
  - 5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene-cyanamide;
  - 5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione 2-(O-methyl-oxime);
  - 5-Benzo[1,3]dioxol-5-ylmethylene-2-benzylimino-thiazolidin-4-one;
  - 2-Benzylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;
  - $\hbox{$2$-Propylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;}$
  - $5\text{-}Benzo[1,3] dioxol\text{-}5\text{-}ylmethylene\text{-}2\text{-}propylimino\text{-}thiazolidin\text{-}4\text{-}one;} \ \underline{and}$
  - 5-(4-Dimethylamino-quinazolin-6-ylmethylene)-2-methylamino-thiazol-4-one.

Claim 15 (Withdrawn): The method of claim 12, wherein the at least one disease is selected from the group consisting of multiple sclerosis, psoriasis, rheumatoid arthritis,

systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis, meningitis, encephalitis, and combinations thereof.

Claim 16 (Withdrawn): The method of claim 12, wherein the at least one disease is selected from the group consisting of Alzheimer's disease, Huntington's disease, CNS trauma, stroke, ischemic conditions, and combinations thereof.

Claim 17 (Withdrawn): The method of claim 12, wherein the at least one disease is selected from the group consisting of atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure, vasoconstriction, and combinations thereof.

Claim 18 (Withdrawn): The method of claim 12, wherein the at least one disease is selected from the group consisting of chronic obstructive pulmonary disease, anaphylactic shock, fibrosis, psoriasis, allergic diseases, asthma, stroke, ischemic conditions, ischemia-reperfusion, platelet aggregation, platelet activation, skeletal muscle atrophy, skeletal muscle hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastisis, melanoma, Karposi's sarcoma, sepsis, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial injuries in the lung, epithelial injuries in the lung, general lung airway inflammation, and combinations thereof.

Claim 19 (Withdrawn): A method of inhibiting PI3 kinase activity, comprising inhibiting PI3 kinase activity with the imino-azolinone-vinyl fused-benzene compound or its salt of claim 1.

Claim 20 (Withdrawn): The method of claim 19, wherein said PI3 kinase is a PI3 kinase  $\gamma$ .

Claim 21 (Currently Amended): A pharmaceutical composition comprising at least one thiazolidinone-vinyl fused-benzene derivative compound or its salt according to claim 1 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

Claim 22 (Withdrawn): A method of preparing a 2-imino-azolinone-vinyl fused-benzene compound or its salt of Formula (I) according to claim 1 comprising derivatizing the imine of Formula Ia with the group G to form the vinyl fused-benzene derivative or its salt

wherein L is a leaving group.